Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 17/20 | 0.49 |
| ▸ | HTR2A | P28223 | 17/20 | 0.49 |
| ▸ | DRD3 | P35462 | 17/20 | 0.49 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | SLC9A5 | Q14940 | 1/20 | 0.45 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9934153 | 0.88 | HTR2C (0.46) | DRD2HTR2ADRD3SLC9A1 | |
| SCHEMBL9977563 | 0.80 | DRD2 (0.62) | DRD2HTR2ADRD3 | |
| SCHEMBL17781855 | 0.79 | SLC9A1 (0.46) | DRD2HTR2ADRD3SLC9A1MTNR1B | |
| SCHEMBL19699408 | 0.79 | SLC9A1 (0.46) | DRD2HTR2ADRD3SLC9A1MTNR1B | |
| SCHEMBL19690310 | 0.79 | SLC9A1 (0.46) | DRD2HTR2ADRD3SLC9A1MTNR1B | |
| SCHEMBL8489071 | 0.77 | SLC9A1 (0.53) | DRD2HTR2ADRD3SLC9A1MTNR1B | |
| SCHEMBL8489075 | 0.77 | MTNR1B (0.56) | DRD2HTR2ADRD3SLC9A1MTNR1B | |
| SCHEMBL14276384 | 0.75 | SLC9A1 (0.50) | DRD2HTR2ADRD3SLC9A1MTNR1B | |
| SCHEMBL18427098 | 0.74 | DRD2 (0.46) | DRD2HTR2ADRD3 | |
| SCHEMBL6680857 | 0.74 | MTNR1B (0.64) | DRD2HTR2ADRD3SLC9A1MTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2931708-B1 | CYCLOPROPYLBORONIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF | DIVERCHIM (FR) | 2017-05-10 | — | — | EP | disclosed |
| US-8558017-B2 | Ruthenium (II) catalysts for use in stereoselective cyclopropanations | VANDA PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130023662-A9 | RUTHENIUM (II) CATALYSTS FOR USE IN STEREOSELECTIVE CYCLOPROPANATIONS | VANDA PHARMECEUTICALS INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-20120149906-A1 | RUTHENIUM (II) CATALYSTS FOR USE IN STEREOSELECTIVE CYCLOPROPANATIONS | VANDA PHARMECEUTICALS INC. (US) | 2012-06-14 | — | — | US | disclosed |
| EP-1027043-B1 | BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149906-A1 | RUTHENIUM (II) CATALYSTS FOR USE IN STEREOSELECTIVE CYCLOPROPANATIONS | RUVBL2, SPR, RUVBL1 | DRD2 833/4885HTR2A 2403/4885DRD3 1232/4885 |
| US-20130023662-A9 | RUTHENIUM (II) CATALYSTS FOR USE IN STEREOSELECTIVE CYCLOPROPANATIONS | RUVBL2, SPR, RUVBL1 | DRD2 833/4885HTR2A 2403/4885DRD3 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.